Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
128
Employees128
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
128
Employees128

STOK Key Statistics

Market cap
1.64B
Market cap1.64B
Price-Earnings ratio
43.49
Price-Earnings ratio43.49
Dividend yield
Dividend yield
Average volume
941.65K
Average volume941.65K
High today
$30.12
High today$30.12
Low today
$28.55
Low today$28.55
Open price
$29.43
Open price$29.43
Volume
1.14M
Volume1.14M
52 Week high
$38.69
52 Week high$38.69
52 Week low
$5.35
52 Week low$5.35

Stock Snapshot

Stoke Therapeutics(STOK) stock is priced at $28.88, giving the company a market capitalization of 1.64B. It carries a P/E multiple of 43.49.

As of 2026-01-19, Stoke Therapeutics(STOK) stock has fluctuated between $28.55 and $30.12. The current price stands at $28.88, placing the stock +1.2% above today's low and -4.1% off the high.

The Stoke Therapeutics(STOK)'s current trading volume is 1.14M, compared to an average daily volume of 941.65K.

During the past year, Stoke Therapeutics(STOK) stock moved between $5.35 at its lowest and $38.69 at its peak.

During the past year, Stoke Therapeutics(STOK) stock moved between $5.35 at its lowest and $38.69 at its peak.

STOK News

Simply Wall St 3d
Stoke Therapeutics Is Down 13.1% After Accelerating EMPEROR Trial Timeline And FDA Talks - Has The Bull Case Changed?

Earlier in January 2026, Stoke Therapeutics said it had accelerated timelines for completing enrollment in its Phase 3 EMPEROR trial of zorevunersen for Dravet...

Stoke Therapeutics Is Down 13.1% After Accelerating EMPEROR Trial Timeline And FDA Talks - Has The Bull Case Changed?
Simply Wall St 4d
Is It Too Late To Revisit Stoke Therapeutics After A 226% One-Year Surge?

If you are wondering whether Stoke Therapeutics at around US$30.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stoc...

Is It Too Late To Revisit Stoke Therapeutics After A 226% One-Year Surge?

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .